BSE Live
Oct 10, 16:01Prev. Close
1118.95
Open Price
1125.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 10, 15:56Prev. Close
1119.90
Open Price
1125.40
Bid Price (Qty.)
1130.30 (523)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Aurobindo Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 12,934.53 | 11,938.70 | 10,041.96 | 9,539.36 | 9,078.96 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 33.25 | 174.16 | 156.58 | |
Revenue From Operations [Net] | 12,934.53 | 11,938.70 | 10,008.71 | 9,365.20 | 8,922.38 | |
Total Operating Revenues | 13,266.48 | 12,257.89 | 10,269.90 | 9,607.05 | 9,166.18 | |
Other Income | 403.37 | 199.22 | 80.65 | 135.95 | 188.36 | |
Total Revenue | 13,669.85 | 12,457.11 | 10,350.55 | 9,743.00 | 9,354.54 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 6,747.55 | 6,455.30 | 4,893.27 | 4,604.19 | 4,425.80 | |
Purchase Of Stock-In Trade | 5.51 | 14.25 | 3.72 | 11.21 | 6.31 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | -229.53 | -289.80 | -337.20 | 31.32 | -141.59 | |
Employee Benefit Expenses | 1,561.47 | 1,362.77 | 1,131.64 | 927.30 | 807.05 | |
Finance Costs | 240.94 | 230.86 | 52.89 | 45.16 | 229.31 | |
Depreciation And Amortisation Expenses | 470.48 | 413.03 | 354.83 | 286.17 | 263.00 | |
Other Expenses | 2,495.73 | 2,306.08 | 1,908.46 | 1,659.08 | 1,616.82 | |
Total Expenses | 11,292.15 | 10,492.49 | 8,007.61 | 7,564.43 | 7,206.70 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 2,377.70 | 1,964.62 | 2,342.94 | 2,178.57 | 2,147.84 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 2,377.70 | 1,964.62 | 2,342.94 | 2,178.57 | 2,147.84 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 505.86 | 426.61 | 505.34 | 462.06 | 518.23 | |
Less: MAT Credit Entitlement | 0.00 | 48.05 | 43.32 | 64.28 | 0.00 | |
Deferred Tax | -0.90 | 56.33 | 68.15 | 74.03 | 2.91 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 504.96 | 434.89 | 530.17 | 471.81 | 521.14 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 1,872.74 | 1,529.73 | 1,812.77 | 1,706.76 | 1,626.70 | |
Profit/Loss From Continuing Operations | 1,872.74 | 1,529.73 | 1,812.77 | 1,706.76 | 1,626.70 | |
Profit/Loss For The Period | 1,872.74 | 1,529.73 | 1,812.77 | 1,706.76 | 1,626.70 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 31.96 | 26.11 | 30.94 | 29.16 | 27.85 | |
Diluted EPS (Rs.) | 31.96 | 26.11 | 30.94 | 29.16 | 27.85 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 15.15 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 122.76 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 175.78 | 146.48 | 219.71 | 114.11 | 134.37 | |
Tax On Dividend | 9.66 | 13.86 | 44.73 | 23.23 | 27.36 | |
Equity Dividend Rate (%) | 300.00 | 250.00 | 250.00 | 250.00 | 250.00 |
09.10.2025
11.09.2025
Aurobindo Pharma shares rise 4.5% as report says GTCR strikes $4.8-bn deal to buy Zentiva
08.09.2025
Aurobindo Pharma shares fall on eight observations from USFDA
08.09.2025
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
27.05.2025
Aurobindo Pharm Standalone March 2025 Net Sales at Rs 2,731.99 crore, down 5.6% Y-o-Y
12.02.2025
Aurobindo Pharm Standalone December 2024 Net Sales at Rs 2,916.63 crore, up 8.34% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL